Becton, Dickinson and Company · NYSE:BDX
Becton, Dickinson and — Conference Presentation (May 2021)
15 slides from Becton, Dickinson and's conference presentation, May 5, 2021
Slide 1: The critical role of public-private engagement in serving vaccine administration needs
"The critical role of public-private engagement in serving vaccine administration needs: Learning from the COVID-19 pandemic” Marie-Liesse Le Corfec Daniel Smith Global Portfolio Marketing Head Program Leader, U.S. Vaccination BD Medical – Pharmaceutical Systems Campaign BD Medical - Medication Deli
Slide 2: Global COVID-19 vaccine rollout requires involvement of multiple stakeholders
The global COVID-19-vaccine rollout requires involvement of multiple stakeholders coordinating through many challenges COVID pandemic unprecedented challenge Wide range of challenges from research & development till vaccine delivery Multiple stakeholders across public & private organizations Increas
Slide 3: The challenge of delivery of the vaccines includes packaging and administration material
The challenge of delivery of the vaccines includes packaging and administration material Around 68.4% of the global adult population is willing to receive covid-19 vaccination 1 Among the current challenges in immunization are: • Vial and syringes shortage 2 • Covid-19 vaccine waste concerns 3 Poten
Slide 4: Developing the COVID-19 vaccine is only half the challenge
Developing the COVID-19 vaccine is only half the challenge. Delivering it correctly is equally critical. Speed to Market Continuity Market Success Vaccine Approach Supply Management Vaccine Delivery • Clinical approach based on • Capacity • Training & Education vaccine presentation • Demand Projecti
Slide 5: Immunization planning and preparedness
Immunization planning and preparedness Actions required to achieve full-scale vaccination and mitigate potential shortages Calibrate supply needs & Public entities managing supply New injection device capacity capabilities for mass vaccination deployment to healthcare providers campaign Partner On I
Slide 6: Key Lessons Learned: Covid-19 Campaigns
Key Lessons Learned: Covid-19 Campaigns Market Overview: Current Landscape and Readiness Approach Assessing capabilities to address unprecedented surge needs • Channel Inventory • Manufacturing Surge Capacity Government Partnership for Preparedness Addressing areas of need for full-scale vaccination
Slide 7: How can prefilled syringes contribute to solve the challenges?
How can prefilled syringes contribute to solve the challenges ? Critical topics of dialogue early in the development Depending on the specificities of the vaccine and its intended use situations …. Pre-filled syringes (PFS) may increase efficiency of workflow PFS may be dose-sparing as compared to v
Slide 8: Pre-filled syringes provides benefits for vaccine administration
Pre-filled syringes provides benefits for vaccine administration Estimation of PFS penetration rate by Patient Safety1 geography 3 • Reduced contaminations (unit sales) • Right dosage* 2018 2028 100 90 87 84 80 71 71 Efficiency2 70 • Reduced administration time, 56 % unit sales 60 workflow convenien
Slide 9: PFS may provide benefits for sparing doses
PFS may provide benefits for sparing doses Average dose wastage rates in a typical vaccination 5-25% vaccine wasted if packed in single2 or program (WHO) multidose vial1 Typical average waste for a liquid Vial Size vaccine • Discarded unused doses1,8,9 • Vial overfill (USP) : 20-25% overfill for a v
Slide 10: The choice of the syringe impacts the volume of packaging and hazardous waste
The choice of the syringe impacts the volume of packaging and of hazardous waste Example of volume of vaccine PFS volume vial container and injection material • For the same injectable volume, the total volume of the PFS can be reduced with a 1mL short luer PFS as opposed to a 1mL long or a Multi do
Slide 11: PFS act as container in a combination product
PFS act as container in a combination product. The vaccine is in contact with various materials – Risks must be assessed Interface & leachable incompatibilities Silicone oil, polymers, glass, elastomers, air bubbles, triple interface[1], etc. Protein degradation[4] (oxidation, deamination, bond clea
Slide 12: Cold chain requirements may impact the choice of a container
Cold chain requirements may impact the choice of a container in case of vaccine technologies requiring deep cold storage Requirements may impact on container, whether vial or pre-fillable syringes Refrigerated Key challenges: vaccines • Ensure usability after cold storage ** • Maintain container clo
Slide 13: Summary
Summary 13
Slide 14: Continuous dialogue and engagement across the vaccine ecosystem will be critical
Continuous dialogue and engagement across the vaccine ecosystem will be critical to further improve vaccination roll out Contract research Massive needs in containers and Pharma companies organizations (CROs) injection delivery tools Contract The choice of container may differ Manufacturing Vaccine
Slide 15: Thank you!
Thank you! 15
Becton, Dickinson and Company — Conference Presentation (May 2021) on 6ix